Auxilium Pharmaceuticals — Merger or Acquisition (September 2014)
13 slides from Auxilium Pharmaceuticals's merger presentation, Sep 16, 2014
Slide 1: Endo-Auxilium: Creating Value, A Compelling Business Combination Proposal
Filedfollowing Subject The Endo September ©2014 by Auxilium: Presents Endo Company: Endo 16,Pharmaceuticals International presentation a2014 Value Compelling Auxilium Creating isplc Business Pharmaceuticals, to Inc. (Commission Proposal beAll used rights Combination during reserved. File Inc. Endo’s
Slide 2: Additional Information
Additional ADDITIONAL This combination or prospectus, SECURITY CAREFULLY statement CERTAIN Endo regarding SEC sources included All the 2© 2014 more SEC related trademarks, communication on and Endo indicated March registration by incertain the (if logos INFORMATION Information any proxy Endo HOLDERS
Slide 3: Forward-Looking Statements
Forward-Looking This but “look forward-looking place SEC Form looking limited with to plans; combined and governmental operations facilities, business All hereof. 3© law. 2014 Auxilium are forward-looking the communication Endo; and undue 8-K forward,” •not Endo to: combined unpredictable if stateme
Slide 4: Proposed Transaction Overview
Proposed Transaction 25% Premium: Consideration: Financing: 4© 2014 to Endo Auxilium’s Transaction Price: Endo Value: Pharmaceuticals Approximately $28.10 intends $2.2 closing Overview per billion to price fund share Inc. equal transaction on inAll September cash mix rights and of cash through reser
Slide 5: Endo's Substantial Opportunity
Endo’s Substantial Opportunity The Enhance Expand Generate Create 5© 2014 combination opportunity company Endo Proposal proposal R&D the significant premium to long Pharmaceuticals capabilities participate provides with isof term Value toEndo synergy and enhanced maximize organic Creating immediate
Slide 6: Substantial Offer for Auxilium Shareholders
Substantial Offer Endo 44% 25% 28% 35% Premium Endo’s 6© 2014 42% 24% offer Price Endo proposal toprice Value Premium 9/12/14 Pharmaceuticals represents offor $28.10 Close Auxilium Premium per substantial Inc. share, Shareholders Alltomix rights premium 30 of Daycash reserved. VWAP for andAuxilium s
Slide 7: Demonstrated Record of Value Enhancing Transactions
Demonstrated Paladin Establish Boca Expand Grupo Add Sumavel® Leverage 7© 2014 significant platform Pharmacal Farmaceutico Endo Labs global generics Irish commercial DosePro® Pharmaceuticals for for Record domicile footprint near-term in cash R&D organic August Somar and capabilities in of platform
Slide 8: Meeting Endo's Strategic Direction
Endo Meeting Maximizing Continued Lean Pursuing Value Addition Opportunity Combined Enhanced Combination 8© 2014 and executing creating Endo or of accretive efficient operating investment companies exceeding Auxilium’s the for Pharmaceuticals Aligns will combination strategic Xiaflex® growth enhance
Slide 9: Compelling Strategic Rationale
Compelling Auxilium’s Endo Drive Support Optimize Combined Highly 9© 2014expects increased Endo complementary development Auxilium’s company 12 Strategic Pharmaceuticals toFDA-approved adoption optimize will broader Rationale ofportfolio Xiaflex® be and Auxilium’s well portfolio continued Inc. produ
Slide 10: Select Highlights of Complementary Product Portfolio
Select Highlights Men’s ©2014 10 Health Endo Pharmaceuticals / Urology of Complementary Orthopedics Inc. All/Product rights Pain Other reserved. Portfolio Specialty
Slide 11: Strong Pro Forma Financial Profile
Strong Enhanced Significant Robust Immediate Deal Synergies ©2014 11 structure Pro Endo financial driven would near accretion Forma synergy Pharmaceuticals enables and returns be byFinancial long opportunity in complementary and continued addition that term enhanced Profile are revenue Inc. to leads
Slide 12: Endo's Substantial Opportunity; Prepared to Engage
Endocombination Endo’s Substantial Opportunity The Enhance Expand Generate Create Proposal ©2014 12 Prepared opportunity company Endo proposal R&D the subject significant premium to long Pharmaceuticals capabilities to participate provides with to of term Engage to the Endo synergy and enhanced maxi
Slide 13: Endo-Auxilium: Creating Value
Endo—Auxilium: Endo September ©2014Presents Endo16,Pharmaceuticals a2014 Value Compelling CreatingInc. Business Proposal All rights Combination reserved.
Auxilium Pharmaceuticals — Merger or Acquisition (September 2014) on 6ix